about
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in MalaysiaTrends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007Mortality among methadone maintenance clients in China: a six-year cohort studyInvolvement in Specific HIV Risk Practices among Men Who Use the Internet to Find Male Partners for Unprotected Sex.Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.'South Asian cocktail'--the concurrent use of opioids, benzodiazepines and antihistamines among injecting drug users in Nepal and associations with HIV risk behaviour.Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States.HIV prevention for people who use substances: evidence-based strategies.Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis.Prevention and treatment of HIV/AIDS among drug-using populations: a global perspectiveSetting the bar high or setting up to fail? Interpretations and implications of the EXPLORE Study (HPTN 015).Participant and staff experiences in a peer-delivered HIV intervention with injection drug usersAdvantages of Joint Modeling of Component HIV Risk Behaviors and Non-Response: Application to Randomized Trials in Cocaine-Dependent and Methamphetamine-Dependent Populations.Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network.Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058The urgency of providing comprehensive and integrated treatment for substance abusers with HIVThe use of the Risky Sex Scale among adolescents receiving treatment services for substance use problems: factor structure and predictive validity.Improving public health through access to and utilization of medication assisted treatmentExamining the spatial distribution of law enforcement encounters among people who inject drugs after implementation of Mexico's drug policy reform.Adolescent health-risk sexual behaviors: effects of a drug abuse intervention.HIV infection and risk of overdose: a systematic review and meta-analysisNIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs.Substance use and hepatitis C: an ecological momentary assessment study.Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.Methamphetamine use is associated with childhood sexual abuse and HIV sexual risk behaviors among patrons of alcohol-serving venues in Cape Town, South Africa.HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients - a pilot study.Factors associated with inability to access addiction treatment among people who inject drugs in Vancouver, CanadaAssociation between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.Substance use disorders and HIV/AIDS prevention and treatment intervention: research and practice considerations.Not just the needle: the state of HIV-prevention science among substance users and future directionsHigh rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes.Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective studyConcurrent substance abuse is associated with sexual risk behavior among adults seeking treatment for prescription opioid dependence.Nonmedical prescription drug users in private vs. public substance abuse treatment: a cross sectional comparison of demographic and HIV risk behavior profilesA novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San FranciscoMethadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment responseSubstance abuse treatment utilization, HIV risk behaviors, and recruitment among suburban injection drug users in Long Island, New York.
P2860
Q27692554-984D1CBE-DA18-4F1D-87C2-08E67E088F01Q28485456-1AE0FF64-6101-442B-95E5-F502162BD621Q28533642-50614DFA-29BA-4791-A570-AF14D3EED09CQ28537626-127B92D8-2602-49AE-8E6E-16F8233DC2A4Q33559814-99DF908A-7E52-48F6-8ADC-DAE22B071356Q33595868-8438EDFC-C5BA-42D1-9519-5A068125F17CQ33672803-F2A534C6-6C23-4CED-924B-FEE6F515584EQ33696533-C131EBB9-BF12-47ED-8AD2-5789ADAF8952Q33924466-4C49690F-6A94-4DA4-87E7-29FFCDEB5E11Q34154119-D048BB78-E5B7-48A8-B1F2-92F38CF1D862Q34259367-AD539FBD-94C2-4E4D-A140-907BC7904565Q34780130-524E3D09-9547-4673-9D22-DBCA43E9F39DQ34986930-50CC8C96-0F49-4F16-918C-E759B86BA3D3Q35054128-FD789110-57F3-42B6-AFC4-C7438A502E18Q35098069-88B2FBDF-5EC5-40DD-8C8F-F8999B188E6BQ35185527-F3B82BCE-47E8-4B6C-A569-DB90C44F9E48Q35244943-470AE79B-D057-4EE8-9C45-B052AF5D249BQ35308404-BC527230-147E-4562-9956-0E9CE2A483D9Q35483358-DA53A934-9A32-4116-B3B5-4D437ACCC45DQ35534893-DEC8C6E0-37BE-45A5-9207-4C96E2EBE231Q35543337-483CD739-4BB4-42B2-8126-2B488D596977Q35547530-FEF95E8B-EAD5-4D1C-A5C1-2FD17CB0B26DQ35898498-12D41308-BD78-4190-9CEF-917A9472D830Q35990579-2D8559FB-3AAB-483D-ACF9-4E1531FCBC1AQ36073120-95A56F80-2DA9-4B23-85CD-68945A765818Q36115179-31E6CBB2-7D01-4736-9A0F-91F99057F233Q36301137-C4C5A117-E09F-4A7C-B8B8-3D5BD1C1F388Q36356899-A655252D-5E74-4EE3-8690-6342ACCBE75CQ36616450-AB12BF79-0621-4A79-9AB4-6B6B5A757E36Q36745453-503A6A68-D8FD-4108-8F6A-86D0AF448960Q36960952-63DE3CD5-C60B-4AD8-90C4-945280031074Q37084003-4649A50D-D7CA-4AAD-AC02-2D8ABF95D371Q37204765-55747DAE-3755-41A4-8D64-E6D916B6EE80Q37370211-85544796-2043-413C-A5CB-33CFAE03ED32Q37557620-A6E4F78E-D620-4696-9252-0ABEA75697EDQ37558785-48CE8F53-D41C-4671-9FF2-F26B0D11125BQ37570243-5C970F3C-27C6-4371-8B6E-B61BB0D9C6A7Q37671714-7179B2B7-779D-4E29-8003-90BAB913B822Q37700353-0C27953B-E1D1-4674-B056-B92A68E0C754Q39412392-C86485D1-A957-422A-9D55-19086D5C8D74
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug treatment as HIV prevention: a research update
@ast
Drug treatment as HIV prevention: a research update
@en
type
label
Drug treatment as HIV prevention: a research update
@ast
Drug treatment as HIV prevention: a research update
@en
prefLabel
Drug treatment as HIV prevention: a research update
@ast
Drug treatment as HIV prevention: a research update
@en
P2093
P2860
P1476
Drug treatment as HIV prevention: a research update
@en
P2093
Charles P O'Brien
David S Metzger
George E Woody
P2860
P356
10.1097/QAI.0B013E3181F9C10B
P407
P478
55 Suppl 1
P577
2010-12-01T00:00:00Z